

Fighting the Cause of Allergy



February 23, 2018

Subject: Announcing the discontinuation of Pharmalgen® Venom Products

US Headquarters

1700 Royston Lane
Round Rock, TX
78664
T 512 251 0037
F 512 251 5882

alk.net/us

Dear Health Care Provider,

After thorough consideration, ALK has made the decision to discontinue our Pharmalgen® venom product line (lyophilized venom allergenic extracts). Our decision to eliminate the Pharmalgen® product line was very difficult since this was ALK's first product in the North American market and instrumental in establishing our scientific leadership in allergy immunotherapy. Pharmalgen® is no longer a viable product due to production capacity constraints in Horsholm, coupled with the increasing overall costs of production and declining sales of Pharmalgen®.

US Manufacturing Site

35 Channel Drive
Port Washington, NY
11050
T 516 767-1800
F 516-883-4572

alk.net/us

ALK still has inventory of our single dose venom products available and will continue to sell these products on a first-come, first-serve basis until depleted.

Once our inventory is depleted, Hollister-Stier will supply venom extracts in the US market. ALK is committed to support Hollister-Stier as needed to ensure they have ample preparation time to increase production and meet your demands. ALK will continue to offer Hollister-Stier our venom raw material supply. ALK is also working with the FDA to ensure that patient impact is minimized.

Dosing and Administration

Due to this discontinuation, caution should be taken when transitioning patients to new venom extracts. We advise that you check with Hollister-Stier for recommendations related to transitioning patients.

Reporting Adverse Events

Health care providers and patients are encouraged to report adverse events for their patients being treated with Pharmalgen® Venom Products to ALK at 1-844-246-1062 or to SafetyCallCenter@inventivhealth.com. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

We understand that venom immunotherapy is critical to prevent life-threatening reactions and improve your patient's quality of life. ALK is committed to helping physicians maintain uniformity of care for their patients.

Our sincerest apologies for the discontinuation of our Pharmalgen® Venom product line. If you have any questions please do not hesitate to contact your Allergy Consultant, or ALK's Sales Support department at 800-325-7354 or customerservices@alk.net.

Sincerely,

A handwritten signature in black ink, appearing to read 'Jay Bates', with a long horizontal flourish extending to the right.

Jay Bates
Director, Allergy Immunotherapy Business

A handwritten signature in black ink, appearing to read 'C. Ross', written in a cursive style.

Christy Ross
Director, Sales Support & Services